To describe a case and present unique images of a metallic intraocular foreign body that was identified in a 12-year-old male patient who underwent routine magnetic resonance imaging (MRI) to assess neurodevelopmental delay. We present MRI and diagnostic imaging of a metallic intraocular foreign body in a young patient with no known history of trauma or reason for the existence of metal in the eye area. Computed tomography scan was performed to confirm the presence of the intraocular foreign body, followed by optical coherence tomography and electroretinogram to assess visual status. It was determined that no surgical intervention was currently required as no visual impairment or ocular toxicity was identified. The patient continues to be monitored. This case presentation highlights the novel imaging features of a metallic intraocular foreign body, unexpectedly detected with MRI.

Background: Metastatic bone disease (MBD) presents significant challenges in patient management, leading to skeletal-related events (SREs), compromised health-related quality of life, and heightened pain experiences. Denosumab (Dmab) and zoledronic acid (ZA) are bone-modifying agents (BMAs) commonly employed to mitigate the sequelae of MBD. Previous meta-analyses have assessed primary outcomes such as overall survival, pathological fractures, radiation to bone, and the time to SREs within studies. However, a single comprehensive analysis comparing their efficacy across multiple primary and secondary outcomes, as well as cost-effectiveness in specific cancer types, has not yet been conducted. Methods: A literature search identified relevant randomized controlled trials (RCTs), and the primary outcomes included overall survival, pathologic fractures, radiation to bone, and the time to SREs within studies. Secondary outcomes included adverse events, pain, analgesia usage, quality of life, and cost. Results: Meta-analysis revealed that Dmab effectively reduced the need for bone-targeted radiation therapy and was superior to ZA in delaying the time to SREs, except in multiple myeloma. Dmab also reduced pathological fracture incidences in breast cancer patients by 39%. Conclusions: Our analysis suggests that while both agents similarly impact overall survival and disease progression, Dmab offers advantages in SRE reduction and improved HRQoL and pain outcomes with lower rates of opioid usage, albeit with higher risks of hypocalcemia and osteonecrosis in some subgroups. The consensus on cost-effectiveness is mixed and varies based on the cancer type and healthcare system, with some studies favoring Dmab’s superior efficacy and safety, while others find ZA more cost-effective due to its lower cost. This study underscores the potential of Dmab as a preferred BMA for MBD management, especially for high-risk skeletal complications, while highlighting cancer-specific safety considerations. Further research is warranted to refine cancer-specific BMA use and optimize MBD management strategies.

Obesity drives demand for total hip arthroplasty (THA) and total knee arthroplasty (TKA) and increases the risks of infection, wound complications, and revision. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for metabolic optimization, but their perioperative safety and effect on arthroplasty outcomes remain unclear. This study evaluated associations between perioperative GLP-1RA use and postoperative outcomes following THA and TKA. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review identified studies of adults undergoing primary or revision THA/TKA with perioperative GLP-1RA exposure (0–12 months preoperatively or ≤30 days postoperatively). PubMed, MEDLINE, and EMBASE were searched through August 20, 2025. Data on demographics, surgical and medical complications, and resource use were collected at 90 days and 1–2 years. Fixed- and random-effects meta-analyses pooled odds ratios (ORs) with 95% confidence intervals (CIs). Thirteen retrospective cohorts including 1,408,609 patients (39,614 THA; 1,373,771 TKA) were analyzed. GLP-1RA use was associated with reduced 90-day periprosthetic joint infection (OR: 0.77; 95% CI: 0.66–0.89), lower 90-day all-cause revision (OR: 0.88; 95% CI: 0.82–0.95), and decreased 90-day readmission (OR: 0.79; 95% CI: 0.70–0.89). A 1-year increase in periprosthetic fracture risk was observed (OR: 1.49; 95% CI: 1.08–2.07), mainly in TKA. No associations were seen for venous thromboembolism, pulmonary embolism, renal failure, pneumonia, cardiac arrest, or aspiration. Perioperative GLP-1RA use in THA and TKA improves early infection, revision, and readmission outcomes without increasing short-term medical or aspiration risk. The observed 1-year fracture risk warrants further study. Prospective trials are needed to define optimal timing and patient selection.